This article seems to suggest that there are problems with the new drug pipeline. Hence drugs with pedigree like Invion's assets may be increasing in value, due to a lack of new drugs making making it to phase II.
http://www.sciencebasedmedicine.org/what-does-a-new-drug-cost-part-ii-the-productivity-problem/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.336M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 11.0¢ | 9.5¢ | $25.88K | 255.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 220 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 124684 | 4 |
View Market Depth
| Last trade - 15.59pm 30/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |